Blueshift Asset Management LLC Buys New Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Blueshift Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 41,086 shares of the company’s stock, valued at approximately $740,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Bridgewater Associates LP lifted its holdings in shares of Teva Pharmaceutical Industries by 5.2% during the 3rd quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock worth $418,000 after acquiring an additional 1,144 shares during the period. Townsquare Capital LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter worth approximately $709,000. D.A. Davidson & CO. boosted its holdings in shares of Teva Pharmaceutical Industries by 6.5% in the 3rd quarter. D.A. Davidson & CO. now owns 86,511 shares of the company’s stock valued at $1,559,000 after purchasing an additional 5,257 shares during the last quarter. FMR LLC grew its stake in shares of Teva Pharmaceutical Industries by 49.5% during the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after buying an additional 20,762,226 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Teva Pharmaceutical Industries by 5.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 432,402 shares of the company’s stock worth $7,792,000 after buying an additional 24,248 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $16.57 on Thursday. The company has a market capitalization of $18.77 billion, a PE ratio of -19.49, a P/E/G ratio of 1.30 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock’s 50 day moving average is $17.60 and its two-hundred day moving average is $17.35. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.